^
    11ms
    High p16INK4A expression in glioblastoma is associated with senescence phenotype and better prognosis. (PubMed, Neoplasia)
    The released CCL13 enhances the infiltration of T cells within the tumor, potentially contributing to the improved prognosis observed in patients with high p16INK4A expression. These findings suggest that tumor cells with a senescence phenotype in GBM, through the secretion of chemokines such as CCL13, may augment immune cell infiltration and potentially enhance patient outcomes by creating a more immunologically active tumor microenvironment.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    EGFR mutation • EGFR amplification • CDKN2A deletion • TERT mutation • TERT promoter mutation • CDKN2A expression
    12ms
    Comprehensive Analysis Reveals No Significant Correlation Between p16/CDKN2A Expression and Treatment Outcomes in Laryngeal Squamous Cell Carcinoma. (PubMed, Head Neck)
    While this study observes trends suggesting that low p16 protein expression is associated with longer DFS and advanced TNM stage in laryngeal cancer, the multivariate analysis did not establish p16 as an independent prognostic factor. These findings suggest that while p16 may have a biological role in tumor progression, its utility as a standalone prognostic marker in clinical outcomes requires further validation.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    CDKN2A deletion • CDKN2A expression
    1year
    Tissue factor signalling modifies the expression and regulation of G1/S checkpoint regulators: Implications during injury and prolonged inflammation. (PubMed, Mol Med Rep)
    It is hypothesised that the balance of this signal is also dependent on the ability of cells to moderate the TF, and therefore on the level of damage. However, prolonged exposure of cells for example due to inflammation, leads to the dysregulation of the G1/S checkpoint by the tumour suppressors, leading to aberrant growth.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • NES (Nestin)
    |
    NES expression • CDKN2A expression
    1year
    HPV is an essential driver in recurrence of cervical cancer. (PubMed, Pathol Res Pract)
    In high-risk HPV-positive CC patients, HPV seems to play a role in recurrent disease. Our findings support ongoing research on targeting HPV oncogenes in CC, also in metastatic disease.
    Journal
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1)
    |
    TP53 mutation • RB1 mutation • CDKN2A negative • TP53 expression • RB1 mutation + TP53 mutation • CDKN2A expression
    1year
    p16Ink4a-induced senescence in cultured mast cells as a model for ageing reveals significant morphological and functional changes. (PubMed, Immun Ageing)
    The inducible expression of p16Ink4a imposes MC senescence, providing a model for tracking the autonomous changes that occur in MCs during ageing. These changes include both morphological and functional alterations. In particular, the increased release of small EVs by senescent MCs suggests an enhanced ability to modulate neighbouring cells.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
    |
    CDKN2A expression
    1year
    Metallophosphoesterase-Domain-Containing Protein 2 (MPPED2) Expression in High-Risk Human Papilloma Virus-Induced Cervical Carcinoma and Its Correlation With p16INK4A Protein. (PubMed, Cureus)
    A significant linear correlation (p=0.000) is found between the p16INK4A and MPPED2 proteins. Conclusion It may support the therapeutic application of MPPED2 protein to prevent cervical carcinoma progression in the near future.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    CDKN2A expression
    1year
    Aging and senescent fates of oligodendrocyte precursor cells in the mouse brain. (PubMed, NPJ Aging)
    We identified age-increased p16/Cdkn2a-expressing OPCs enriched for senescence-related pathways and distinct senescence signatures between hippocampus and fimbria. Aged brain OPC populations differ in microenvironment properties and responses to senescence-directed intervention.
    Preclinical • Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    CDKN2A expression
    1year
    Potential Prognostic Role of Protein Kinase D Isoforms in Head and Neck Cancers. (PubMed, Int J Mol Sci)
    However, the role of PKD3 was elusive in some cancers. Our findings suggest that testing for PKD isotypes with immunohistochemistry may support the diagnostic estimation of tumor progression and prognosis in HNSCC with a potential therapeutic relevance.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • PKD1 (Polycystin 1) • PKD2 (Polycystin 2) • PKD3 (Polycystic Kidney Disease 3) • PRKD1 (Protein Kinase D1)
    |
    CDKN2A expression
    1year
    P16INK4A drives RB1 degradation by UTP14A-catalyzed K810 ubiquitination. (PubMed, iScience)
    Our findings indicate that there is a negative feedback loop between P16INK4A and RB1 expression and that disruption of this loop may partially rescue the biological outcomes of P16INK4A loss. We also revealed a hitherto unknown function for P16 INK4A in regulating proteome-scale ubiquitination by inhibiting cell proliferation, which may be useful for the development of anticancer drugs.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CDK4 (Cyclin-dependent kinase 4)
    |
    RB1 expression • CDKN2A expression
    1year
    Frailty and pre-frailty associated with long-term diminished physical performance and quality of life in breast cancer and hematopoietic cell transplant survivors. (PubMed, Aging (Albany NY))
    p16INK4a expression was higher in those who were frail, older than 60, and with higher expression in frail vs. fit patients who are 18-59 years. Our study highlights the high prevalence of frailty in survivors with detrimental effects on physical and overall wellbeing, and supports an association between frailty and the senescence marker p16INK4a.
    Journal • HEOR
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    CDKN2A expression
    1year
    Comparative analysis of PD-L1 expression and molecular alterations in primary versus metastatic lung adenocarcinoma: a real-world study in China. (PubMed, Front Oncol)
    Samples of metastatic tumors exhibited a higher proportion of elevated PD-L1 expression, a greater number of pathway alterations, and a higher occurrence of CDKN2A copy number deletions than primary samples. This highlights the importance of reinforcing the clinical management and follow-up of patients with CDKN2A deficiency, particularly within the subset of stage I lung adenocarcinoma.
    Real-world evidence • Journal • PD(L)-1 Biomarker • IO biomarker • Real-world • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    PD-L1 expression • CDKN2A deletion • CDKN2A expression
    |
    PD-L1 IHC 22C3 pharmDx
    1year
    A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia (clinicaltrials.gov)
    P1/2, N=110, Recruiting, Antiva Biosciences | N=29 --> 110 | Trial completion date: May 2024 --> Jun 2025 | Trial primary completion date: Apr 2024 --> Jun 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    CDKN2A expression